Adapted from the Canadian Healthcare Association’s submission to the House of Commons Standing Committee on Industry currently reviewing Bill C‐91, an Act to amend the Patent Act. Discusses the controversy surrounding this legislation, which extended patent protection to brand‐name drug manufacturers to 20 years before generic copies of pharmaceuticals can be introduced on to the market.
CitationDownload as .RIS
MCB UP Ltd
Copyright © 1997, MCB UP Limited